Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alaunos Therapeutics ( (TCRT) ) has provided an update.
On May 18, 2026, Alaunos Therapeutics reported updated non-GLP preclinical data from diet-induced obesity mouse models evaluating ALN1003, its investigational oral metabolic therapy for obesity and related conditions. The studies showed improvements in insulin-resistance-related biomarkers, adipose endocrine markers such as adiponectin-to-leptin ratio, and qualitative liver histology findings suggesting reduced hepatic steatosis and lower NAS scores, indicating multi-axis engagement of metabolic syndrome biology.
The company highlighted that ALN1003 has not yet been tested in humans and that the findings are limited by small sample sizes and qualitative assessments, but said the data support further preclinical work in metabolic syndrome, MASLD and insulin resistance. Alaunos ended March 31, 2026 with approximately $0.354 million in cash and expects its runway to extend into the second quarter of 2026, and it plans to seek additional financing to fund operations and continued advancement of its preclinical obesity and metabolic disorders program.
Spark’s Take on TCRT Stock
According to Spark, TipRanks’ AI Analyst, TCRT is a Neutral.
Alaunos Therapeutics’ overall score is primarily impacted by its weak financial performance with ongoing losses and negative cash flows. While the technical analysis shows some positive momentum, the negative P/E ratio and lack of dividends underscore valuation challenges. The absence of earnings call and corporate events information further limits the stock’s appeal.
To see Spark’s full report on TCRT stock, click here.
More about Alaunos Therapeutics
Alaunos Therapeutics is a biotechnology company focused on developing novel therapeutics, with a particular emphasis on obesity and metabolic disorders. Its lead program, ALN1003, is an oral small-molecule metabolic candidate positioned as a differentiated, non-hormonal alternative to existing therapies, targeting insulin resistance, adipose tissue signaling and hepatic lipid metabolism.
Average Trading Volume: 15,257
Technical Sentiment Signal: Sell
Current Market Cap: $5.93M
Learn more about TCRT stock on TipRanks’ Stock Analysis page.